SABR for Kidney Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
Renal Cell Carcinoma (RCC) is the most common type of kidney cancer. The usual treatment for this type of cancer is surgery. Considering the most common patients are an average age of 65 and some are not suitable candiates for surgery, there is great interest in non-surgical alternatives for kidney cancer treatments. This study will investigate the use of Stereotactic Ablative Radiosurgery (SABR) for renal tumors. SABR is a non-invasive alternative, which involves delivery of high doses of radiation to the target, while minimizing the risk of injury to the surrounding organs. Patients will be seen before and end of treatmetn and will be followed at 4 month intervals for up to 2 years. During the follow ups, patients will be asked to complete a quality of life questionnaire and will have standard of care imaging.
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications, but it does mention that systemic therapy (except hormone therapy) should not be taken within 6 days before starting the trial treatment.
Is SABR safe for treating kidney cancer?
How is the treatment SABR different from other treatments for kidney cancer?
What data supports the effectiveness of the treatment SABR for kidney cancer?
Who Is on the Research Team?
Andrew McPartlin, MD
Principal Investigator
The Princess Margaret Cancer Foundation
Are You a Good Fit for This Trial?
This trial is for patients with a solid kidney mass suitable for SABR treatment, specifically those who have primary RCC or metastasis up to 6cm. It's aimed at people who are high-risk for surgery or have declined it, and can still perform daily activities (ECOG status 0-3). Those with multiple active metastases, recent systemic therapy, prior overlapping abdominal radiotherapy, end-stage renal failure, or certain genetic syndromes cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Stereotactic Ablative Radiosurgery (SABR) for renal tumors
Follow-up
Participants are monitored for safety and effectiveness after treatment, including quality of life assessments and standard of care imaging
What Are the Treatments Tested in This Trial?
Interventions
- SABR
SABR is already approved in European Union, United States, United Kingdom for the following indications:
- Early-stage non-small cell lung cancer
- Liver cancers
- Kidney cancers
- Bone metastasis
- Spinal metastasis
- Prostate cancers
- Early-stage non-small cell lung cancer
- Liver cancers
- Kidney cancers
- Bone metastasis
- Spinal metastasis
- Prostate cancers
- Early-stage non-small cell lung cancer
- Liver cancers
- Kidney cancers
- Bone metastasis
- Spinal metastasis
- Prostate cancers
Find a Clinic Near You
Who Is Running the Clinical Trial?
University Health Network, Toronto
Lead Sponsor